Skip to main content

Balyasny Asset Management L.P.

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1218710 Chicago, IL

Position in ACAD

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$6,966,979
+$6,966,979 QoQ
Shares Held
312,982
Ownership
0.183%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Jun 2020
13 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in ACAD Over Time

Shares Held

Position Value (USD)

Derivatives in ACAD

reported options exposure · as of Mar 31, 2025
CallValue
$1,661,000
CallShares
100,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Balyasny Asset Management L.P. holds $2,162,785,356 across 177 Biotechnology names. ACAD ranks #79 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in ACAD

Export CSV
16 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $6,966,979 312,982
2025-03-31 $1,661,000 100,000
2024-12-31 $7,283,518 396,922
2024-09-30 $17,295,917 1,124,572
2024-06-30 $12,547,372 772,146
2024-06-30 $3,250,000 200,000
2023-12-31 $9,420,395 300,875
2023-12-31 $3,131,000 100,000
2023-09-30 $340,067 16,318
2022-12-31 $41,041 2,578
2022-06-30 $146,395 10,390
2021-12-31 $1,999,934 85,687
2021-09-30 $2,142,324 128,978
2020-09-30 $6,187,500 150,000
2020-09-30 $2,799,390 67,864
2020-06-30 $377,678 7,792